3 Reasons Viemed Healthcare Could Keep Growing
CEO Casey Hoit explains how Viemed’s clinician-first, capital-light model drives growth in complex respiratory and adjacent markets.
We unpack product mix, regulatory tailwinds, AI efficiency gains, and the key risks investors must weigh.
– Interview with CEO Casey Hoit on strategy, culture, and disciplined M&A.
– Business mix: ventilator care ~50% of revenue; sleep ~21% (up ~60% YoY); plus oxygen, resupply, staffing, and maternal health.
– Reimbursement: bundled rental model (~$1,000 per ventilator patient/month) and favorable regulatory changes including NCD enforcement and removal from competitive bidding.
– Growth and efficiency: roughly 26% CAGR since IPO, recent quarter ~21% revenue growth, and AI tools to automate audits and revenue-cycle tasks.
– Key risks for investors: payer behavior, staffing and training constraints, audit/compliance exposure, and execution of value-based contracting.
————————————————————————
This video is brought to you by The Motley Fool.
Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 986% as of 5/25/2026 and measured against the S&P 500 returns of 208% as of 5/25/2026. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well.
————————————————————————
